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Summary Metallothionein (MT) is an intracellular metal-binding protein which has been implicated in
various biological roles, including heavy-metal detoxification and zinc and copper homeostasis, and has
putative antioxidant properties. High levels of MT have been detected in certain human tumours, but its
functions are unclear. The presence of tumour may cause stress conditions along with alterations in host
metabolism, such as the redistribution of metals and, subsequently, in changes in hepatic MT isoforms. The
distribution of basal levels of MT-I and MT-I1 isoforms in livers of different strains of mice and their
induction in mice inoculated with tumour cells are investigated. While Balb-c, C57/BL and CDI mice strains
had an equal distribution of both hepatic MT isoforms, MT-I and MT-II, C3H and athymic nude mouse
livers contained more MT-I isoform (>80% of total MT) than MT-I1. In addition, MT-I was the
predominant isoform synthesised (>88%) in the livers of all strains of mice at 24 h after injection with either
cadmium or zinc salts. After inoculation with human testicular T7800 or T7799 tumour cells, the major form
of MT induced in the livers of nude (nu/nu) mice was Zn-MT-I, and its concentration was positively correlated
with the size of the inoculated tumours (r2 = 0.85). A similar positive relation was found in the livers of Balb-c
mice inoculated with MM45T mouse bladder tumour cells (r2 = 0.96). Following surgical removal of T7800
tumour, hepatic MT concentrations returned to basal values. There was an increase in plasma MT levels in
tumour-bearing mice and it was positively correlated with the increase in hepatic MT levels. These results
demonstrate a specific increase in hepatic MT-I isoform in tumour-bearing mice, and this may be due to a
generalised stress during tumour growth.
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Metallothioneins (MTs) are implicated in the homeostasis of
zinc and copper, and also in the detoxification of metals
(Hamer, 1986; Richards, 1989; Bremner and Beattie, 1990),
and they also may be involved in the cellular responses to
cytotoxic effects of various chemicals, including antineoplas-
tic agents. A high expression of intracellular MT in certain
human tumours has been shown (Cherian, 1994), and this
may be one of the mechanisms of cellular resistance to
chemotherapeutic drugs such as cis-diamminedichloroplati-
num (II) (cisplatin or cDDP) (Andrews and Howell, 1990;
Johnston et al., 1993). The two major isoforms of MT in
mammalian liver are MT-I and MT-II, which differ in a
single charge at neutral pH and antigenicity. In addition, two
other minor isoforms of MT, MT-III and MT-IV, have been
recently isolated from brain and stratified squamous epithelia
respectively (Palmiter et al., 1992; Quaife et al., 1994). It is
unknown whether one isoform may be more involved in the
resistant phenotype than the other, and the role of MT in the
cDDP-resistant phenotype is still uncertain and remains con-
troversial (Cherian et al., 1993).
Metallothionein was originally identified by its metal-
binding capacity (Margoshes and Vallee, 1957) and later
shown to be induced by a variety of divalent metals such as
cadmium and zinc. Subsequent studies have shown that, in
addition to metals, other factors such as glucocorticoids,
lymphokines, cytokines, irradiation and stress can induce the
synthesis of MT (Kagi and Schaffer, 1988). Moreover, MT
may also play a role in the protection against oxygen free
radicals and inflammation (Matsubara et al., 1987; Naga-
numa et al., 1988). The interaction between the host and the
tumour is important for tumour growth. The tumour obtains
nutrients from the host while, at the same time, releasing
various agents such as cytokines and angiogenic factors into
the circulation which eventually lead to survival and further
growth of the tumour. These circulating factors have the
potential to induce the hepatic synthesis of MT and a tumour
growth-dependent elevation of zinc and MT in the liver has
been observed in rodents bearing solid tumours (Takeda et
al., 1992). The mechanism of MT induction in the livers of
tumour-bearing mice and its effects on the mice are un-
clear.
This study was designed to investigate further the condi-
tions required for MT induction in the livers of tumour-
bearing mice. The hepatic and plasma MT levels in athymic
(nude) mice and Balb-c mice following tumour inoculation as
well as after removal of non-invasive solid tumours were
investigated. A recently developed competitive enzyme-linked
immunosorbent assay (ELISA) with high sensitivity, using
two populations of polyclonal antibodies, has enabled us to
measure two specific MT isoforms (Chan et al., 1992a, b).
Materials and methods
Tumour models
Two human germ cell testicular teratocarcinoma cell sub-
clones, T7800 and T7799, as well as the spontaneous mouse
urinary bladder carcinoma, MM45T, were obtained from the
American Type Culture Collection (Bethesda, MD, USA).
The cell lines, grown as adherent monolayers, were main-
tained in vitro by regular passages in Dulbecco's modified
Eagle medium (DMEM) (Gibco BRL, Burlington, Ontario,
Canada) supplemented with 10% fetal bovine serum (FBS)
(Gibco BRL). Cells in the log phase of growth and detached
with 0.25% trypsin-EDTA were used for inoculation. Cell
viability was determined by trypan blue exclusion (Phillips,
1973).
Animals and treatments
Effect of surgical excision of tumour on hepatic MT levels
Athymic mice (-30 g), at 5 weeks of age, were inoculated
with 1 x 106 T7800 tumour cells and randomly divided into
four groups of five mice to study changes in hepatic MT
levels after surgically removing the tumours. All inoculated
mice showed palpable tumours after 13 days. Tumour
volume (TV) was determined by measuring the longest axis
(a) and perpendicular shortest axis (b) and using the formula
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DecemberTV = 0.4ab2 (Kadhim and Chin, 1988). Tumour volumes
were measured 16 days post inoculation, and two of the four
groups ofmice were sacrificed for hepatic MT determination.
On the same day, the tumours were surgically removed from
one of the two remaining groups. Four days later, the last
two groups of mice were sacrificed and hepatic MT and
tumour volumes determined. Sham operations were perform-
ed in a separate experiment on four mice. The tumours were
analysed for MT levels.
Determination of plasma MT levels Seven athymic mice
(.30 g) were inoculated with 1 x 106 T7800 tumour cells and
14 days later were sacrificed by exanguination from the
abdominal aorta after pentobarbital anaesthesia (60jigkg-').
Whole blood was taken immediately from the animals and
centrifuged at 3000g for 10min to obtain the plasma frac-
tion. Plasma samples were frozen at -80°C until used for
MT determination by an ELISA (Chan et al., 1992a).
Tumour growth in Balb-c mice Seven Balb-c mice (Charles
River, St Constant, Quebec, Canada) were inoculated with
1 x 106 MM45T tumour cells and sacrificed after 18 days.
Liver MT levels and tumour volumes were determined as in
the nude mice above.
Determination of MT isoforms in different strains of mice
The distribution of hepatic MT-I and -II isoforms was deter-
mined in the following mouse strains of males aged 4-6
weeks: nude; Balb-c; C3H (Charles River); C57/BL (Harlan
Sprague Dawley); and CD1 (Harlan Sprague Dawley).
Groups of 4-6 mice from each strain were treated with
either saline (0.5 ml, i.p.), zinc sulphate (10 mg Zn kg-', i.p.),
or cadmium chloride (5 mg Cd kg-', i.p.) 24 h before killing.
Biochemical analyses
Determination of metallothionein Metallothionein levels in
tissue homogenates and plasma were measured by the silver-
haem saturation method (Scheuhammer and Cherian, 1986)
and an ELISA (Chan et al., 1992b) respectively. In certain
experiments, the isoforms of hepatic MT were measured by
an ELISA using two isoform-specific antibodies (Chan et al.,
1992b). For MT determination in cells growing in culture, a
pellet of 1 x 106 cells was resuspended in 1 ml of deionised
distilled water, sonicated to lyse the cells, centrifuged at
8000g for 5 min and the supernatant frozen at -80°C until
use in an ELISA.
Determination of metals Zinc and copper contents in the
liver were determined by flame atomic absorption spectro-
scopy (AAS) (Varian Spectra-30; Varian Canada, George-
town, Ontario, Canada) after digestion with four volumes of
concentrated nitric acid. Sephadex G-75 gel filtration was
used to separate the MT fractions in hepatic supernatant
after homogenising tissue in 0.25 M sucrose and centrifuging
at 10000g for 10min. Fractions around 10000 dalton were
analysed for their zinc and copper content by AAS. The MT
fractions were pooled and MT content confirmed by the
silver-haem method. Protein concentration in the cell super-
natant was determined by the method of Lowry et al.
(1951).
Statistical calculations
The data were analysed by Student's t-test and one-way
analysis of variance (ANOVA).
Results
The two related subclones of the human teratocarcinoma line
differ somewhat in their phenotypes. In vitro, the T7800 and
T7799 tumour cell lines had MT concentrations of 78.8 ± 9.1
and 51.2 ± 4.4 1Lgmg-' protein respectively. Both cell lines
were harvested for MT determination by ELISA during the
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second day oflog growth. But when they were grown in nude
mice for 16 days their MT concentrations were similar
(321g MTg-' tissue). In both these tumour models, when
the nude mice were inoculated with tumours for 16 days,
there was a significant positive correlation (r2 = 0.85,
p<0.05, n = 8) between individual tumour weight and hepa-
tic MT concentrations (data not shown). A similar positive
correlation (r2 = 0.85, P<O.01, n = 7) was observed between
liver and plasma MT levels in T7800 tumour-bearing nude
mice (Figure 1). Similar results were obtained for T7799
bearing mice. Hepatic zinc levels were also elevated in mice
bearing tumours, but the correlation between tumour weight
and hepatic zinc was not statistically significant.
A strong positive correlation (r2 = 0.96, P<0.001, n = 7)
was also obtained between hepatic MT content and tumour
weight in Balb-c mice inoculated with a urinary mouse blad-
der tumour (MM45T) (Figure 2).
Liver supernatants from nude mice bearing T7800 tumours
were fractionated on a Sephadex G-75 column to separate
proteins. The MT fractions contained mainly zinc (-78%)
with a small amount of copper (22%) (Figure 3), indicating
that the hepatic MT induced in tumour-bearing nude mice
contained mainly zinc.
In nude mice whose tumours were completely removed
surgically, liver MT levels returned to basal levels
(8.9 ± 2.5fig MT g-' tissue) within 4 days after surgery
(Figure 4). In control mice with intact, growing tumours,
hepatic MT levels were increased (122 ± 0.31 ggg-' tissue) as
the tumour volume increased from days 16 to 20 following
T7800 tumour inoculation (Figure 4). In sham-operated con-
trol mice, hepatic MT levels (10.6 ± 4fig MTg-1) were not
significantly different from control level.
The predominant isoform in livers of control zinc-treated
and tumour-bearing nude mice was MT-I (Table I), account-
ing for more than 90% of total hepatic MT in all cases. The
total amount of MT in the liver calculated by addition of
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Figure 1 Correlation between hepatic MT and plasma MT in
nude mice bearing T7800 (*) tumours (n = 7). MT was
estimated as described in Materials and methods.
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Figure 2 Correlation between tumour weight and hepatic MT
levels in Balb-c mice inoculated with MM45T tumours (n = 7).
MT was determined by the silver-haem method (Scheuhammer
and Cherian, 1986).
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MT-I and MT-II using ELISA techniques was in good agree-
ment with values obtained by the silver-haem saturation
method (Table I).
In nude mice and C3H mice, the predominant isoform of
saline-treated mice was MT-I, which constituted 84% ± 5%
and 87% ± 2% of total MT respectively. However, there was
an equal distribution (about 50%) of both isoforms MT-I
and MT-II in Balb-c, C57/BL and CD1 mice treated with
saline (Table II). In all mouse strains studied, MT-I isoform
accounted for >88% of the total MT at 24 h after induction
of MT synthesis by either zinc or cadmium ingestion (Table
II).
Discussion
The characterisation of isoform-specific antibodies to MT
(Chan et al., 1992b) allowed identification of MT-I as the
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Figure 3 Sephadex G-75 elution profile of Zn (O) and Cu (0)
from liver cytosol of a nude mouse bearing T7800 tumour. The
elution position of MT is marked by an arrow.
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Figure 4 Effect of surgical removal of T7800 tumour (16 days
post inoculation) on hepatic MT levels in nude mice (O) 4 days
following tumour excision (day 20). Control animals did not
undergo tumour removal. Tumour volumes (0) were determined
on days 16 and 20 (open bars) (P<0.01, values for *tumour
volume and #hepatic MT are different from that determined on
day 16) (n = 5 per group).
predominant isoform that is induced in mouse liver after
inoculation of tumours. It is unclear whether the specific
induction of MT-I in tumour-bearing animals is related to
the type of tumour or strain of mouse. Recent studies in our
laboratory have shown a significant interspecies difference in
the basal level of MT, with MT-II representing the major
isoform in the majority of species with the exception of dog
and mouse (Chan and Cherian, 1993). Other studies (Ker-
shaw et al., 1990) have indicated that in livers of CF-I mice
the MT-I concentration is approximately 2.4 times greater
than that of MT-II after zinc and cadmium injections, where-
as following ethanol and dexamethasone injections MT-I and
MT-II contents were equal. In developing mouse livers (i.e.
for 14 days post parturition), MT-I was more abundant than
MT-II, while in contrast there was no difference observed
between the isoform levels in developing rat livers (Lehman-
McKeeman et al., 1991). The present study revealed vari-
ability in the isoform composition of hepatic MT in different
strains ofmice. Although nude mice and C3H mice appear to
have greater basal levels of MT-I, there was no significant
difference between the two isoforms in control Balb-c, C57/
BL or CD1 mice (Table II). The major isoform that was
induced in all mice studied after zinc or cadmium injections
was MT-I, constituting more than 88% of total MT in all
cases.
After inoculation of tumour, the recipient undergoes a
variety of metabolic changes to accommodate the growth of
the tumour. Earlier studies showed that limiting dietary zinc
inhibited tumour growth in a variety of transplantable
tumours (Petering et al., 1967; DeWys and Pories, 1972;
Minkel et al., 1979; Kraker and Petering, 1983). Inoculation
of Ehrlich cells into mice resulted in a decrease in plasma
zinc and an elevation of hepatic Zn-MT-Il that was depen-
dent on the number of cells injected (Ujjani et al., 1986). In
contrast, it has been reported that high levels of zinc can
exert a marked growth-inhibitory effect on tumours when
zinc is injected directly into animals inoculated with
Table II The percentage ofMT-I isoform in livers ofvarious strains
of mice
Isoform MT-I (%)
Mouse Tumour-
strains Control Zn injected Cd injected bearing
Nude mice 84 5 (3) 99 0.5 (6) 91 ± 11 (4) 98 ± 0.3 (4)
Balb-c 48 ± 5 (4) 98 ± 0.4 (3) ND NA
C3H 87 2 (4) 98 1 (3) ND NA
C57/BL 47 9 (3) 89 5 (4) 93 2 (3) NA
CD1 50 9 (3) 94 2 (3) 96 3 (3) NA
The total hepatic MT and the MT-I isoforms were determined by
ELISA as described in Chan et al. (1992b). The percentage of MT-I
in various strains of mice treated with saline (control), zinc sulphate
(10mg Znkg'1, i.p.) or cadmium chloride (5mg Cd kg-', i.p.) or
inoculated with T7800 tumours for 17 days are reported. Numbers
represent mean percentage ± s.e. Values in parentheses indicate
number of animals per group with three replicate determinations per
animal (ND, not determined; NA, not applicable).
Table I The distribution of hepatic MT isoforms in nude mice treated with saline
(controls), zinc sulphate (200pmol Znkg-', i.p.) or bearing T7800 tumours
Total MT Total MT
Nude mice: MT I MT II (ELISA) (Silver-haem)
treatment (gggg' tissue) (pggg' tissue) (pggg' tissue) (jgg-' tissue)
Control: 15.1 ± 3.7 1.2 ± 0.06 16.3 14.8 + 2.6
no tumour (92%) (8%)
Zn-induced: 250 ± 22 2.2 ± 0.01 252.2 286± 13
no tumour (99%) (1%)
Large tumour 450± 61 7.0± 1.1 457 501 77
bearing (98%) (1%)
Tumour-bearing animals were sacrificed 17 days post inoculation. Comparisons of
total MT measured by ELISA (addition of MT-I and MT-II concentrations) and the
silver-haem saturation method are included. Values indicate mean
concentration ± s.e. Numbers in parentheses represent the percentage contribution of
each isoform to total MT (n = 4 per group).
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leukaemia or sarcoma cells (Woster et al., 1975; Phillips and
Sheridan, 1976). In a recent study, mice transplanted with
various experimental tumour cells exhibited increases in both
hepatic zinc and MT which were correlated with the size of
the tumour (Takeda et al., 1992). Here, we present data
showing that in nude mice inoculated with human T7800 and
T7799 cells both plasma and hepatic MT are increased and
that the increase is positively correlated with the weight of
tumours. These effects were observed in mice bearing much
smaller tumours than previously reported, when hepatic MT
levels were increased in mice bearing tumours which grew to
about 30% of their body weight (Takeda et al., 1992). A
positive correlation between hepatic MT levels and mouse
MM45T tumour size was also observed in Balb-c mice in the
present study. Thus, both human and mouse tumours
induced hepatic MT-I synthesis in mice after inoculation.
The source and reasons for this marked tumour-induced
elevation of Zn-MT-I (up to a 33-fold increase over control,
Table I) in the mouse liver are unclear. Several studies have
demonstrated that cytokines such as interleukin 1 (Cousins
and Leinart, 1988; De et al., 1990), interleukin 6 (De et al.,
1990; Schroeder and Cousins, 1990) tumour necrosis factor
(De et al., 1990) and interferon (Friedman and Stark, 1985;
De et al., 1990) can induce MT synthesis in the liver. It is
conceivable that the tumour may be releasing into the blood-
stream factors such as cytokines which induce MT synthesis
in the liver and then may subsequently be transported to the
plasma. As the tumour grows, the increased compression of
the tumour against organs and body cavities may also result
in elevated stress. It is possible that the stress associated with
tumour growth can cause an increase in hepatic zinc concen-
tration and a concomitant reduction in plasma zinc concen-
tration. This pattern of metal distribution has been shown to
occur in the presence of a variety of stresses, such as
bacterial infections (Sobocinski et al., 1978) and burns.
Plasma zinc was not measured in our present study, but
plasma MT elevation paralleled that ofhepatic MT induction
after tumour inoculation. A direct relationship between the
presence of tumour and hepatic MT induction is suggested
because, 4 days after complete surgical removal of the
tumour, hepatic MT levels returned to normal. These results
suggest the potential use of plasma MT as a tumour marker
in mice. However, there are a number of factors which can
alter plasma MT levels.
In summary, the induction of a specific isoform, MT-I, is
demonstrated in livers of mice bearing both human and
murine tumours. Although the mechanisms of this induction
and the biological function of the elevated hepatic MT is still
unclear, these results indicate that MT may be involved in
the host response to the presence of tumour. This conclusion
is further supported by evidence that MT may be associated
with the acute-phase response in inflammation (Min et al.,
1991). It has been proposed that in proliferating cells of
human tumours, MT may act as a storage protein for zinc
which is required for certain enzymes in replication and
transcription factors (Haile Meskel et al., 1993). If, in fact,
MT does play a significant role in tumour growth (Kontozo-
glou et al., 1989) and cellular drug resistance (Chin et al.,
1993; Satoh et al., 1993), it would be of interest to determine
if there exists an isoform-specific response in tumour cells.
Also, mouse strain differences with respect to basal levels of
the two isoforms of MT may alter the ability of both tumour
and host to respond to chemotherapy. Further studies are
needed to evaluate the clinical usefulness of plasma MT
determinations in detection of tumours in cancer patients.
Abbreviations: MT, metallothionein; cDDP, cisplatin; Zn, zinc; Cd,
cadmium; Cu, copper; ELISA, enzyme-linked immunosorbent assay;
DMEM, Dulbecco's modified Eagle medium; FBS, fetal bovine
serum; s.c., subcutaneous; TV, tumour volume; ANOVA, one-way
analysis of variance.
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